HC Wainwright & Co. Reiterates Overweight on Indaptus Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Overweight and maintains $15 price target.
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $15 price target.
Indaptus Therapeutics Activates Morristown Medical Center as Trial Site For INDP-D101 Phase 1 Open-Label Trial of Decoy20 In Patients With Advanced Solid Tumors
The study's objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to assess Decoy20 pharmacokinetics (PK),
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers OpGen (NASDAQ:OPGN) stock rose 69.6% to $0.21 during Tuesday’s pre-market session. The market value of their outstanding…
Indaptus Therapeutics Announces Initiation Of First-In-Human, Open Label, Dose Escalation And Expansion Multicenter Phase 1 Clinical Trial Of Decoy20 In Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc. (NASDAQ:INDP, ", Indaptus", or ", the Company", )))), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces
Indaptus Therapeutics Q3 EPS $(0.42) Up From $(0.81) YoY
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.42) per share. This is a 48.15 percent increase over losses of $(0.81) per share from the same period last year.
66 Biggest Movers From Friday
Gainers
GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.